Ardelyx, Inc.
Symbol: ARDX (NASDAQ)
Company Description:
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
- Today's Open: $6.57
- Today's High: $6.699
- Today's Low: $6.465
- Today's Volume: 1.42M
- Yesterday Close: $6.53
- Yesterday High: $6.6199
- Yesterday Low: $6.465
- Yesterday Volume: 2.88M
- Last Min Volume: 1.74K
- Last Min High: $6.485
- Last Min Low: $6.485
- Last Min VWAP: $6.485
- Name: Ardelyx, Inc.
- Website: https://www.ardelyx.com
- Listed Date: 2014-06-19
- Location: FREMONT, CA
- Market Status: Active
- CIK Number: 0001437402
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.57B
- Round Lot: 100
- Outstanding Shares: 240.98M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-28 | 4 | View |
| 2025-08-28 | 4 | View |
| 2025-08-26 | 144 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-25 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-04 | 10-Q | View |
| 2025-08-04 | 8-K | View |
| 2025-07-29 | SCHEDULE 13G/A | View |
| 2025-07-03 | 8-K | View |
| 2025-06-25 | SCHEDULE 13G | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |
| 2025-06-23 | 4 | View |